Results 11 to 20 of about 126,067 (267)

Clinical outcomes of paliperidone long-acting injection in patients with schizophrenia: a 1-year retrospective cohort study

BMC Psychiatry, 2021
Background Schizophrenia is a severe psychiatric disorder. Poor medical adherence increases relapse rate. Long-acting injection of antipsychotic agent is developed for improving medical adherence.
Hsue-Wei Chan, Chin-Yu Huang, Yung-Chieh Yen   +2 more
doaj   +2 more sources

Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis [PDF]

BMC Medicine, 2009
Background Most patients with chronic obstructive pulmonary disease (COPD) receive inhaled long-acting bronchodilators and inhaled corticosteroids. Conventional meta-analyses established that these drugs reduce COPD exacerbations when separately compared
ter Riet Gerben, Kleijnen Jos, Bachmann Lucas M, Puhan Milo A, Kessels Alphons G   +4 more
doaj   +2 more sources

Extrapyramidal adverse events and anticholinergics use after the long-term treatment of patients with schizophrenia with the new long-acting antipsychotic Risperidone ISM®: results from matching-adjusted indirect comparisons versus once-monthly formulations of Paliperidone palmitate and Aripiprazole monohydrate in 52-week studies

Annals of General Psychiatry, 2023
Background Risperidone ISM® is a newly developed long-acting injectable (LAI) treatment for schizophrenia in adults. In the absence of head-to-head comparisons with other similar antipsychotics, the objective of this study was to generate indirect ...
Pedro Sánchez, Cecilio Álamo, Marcos Almendros, Max Schlueter, Anastasios Tasoulas, Javier Martínez   +5 more
doaj   +2 more sources

Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events

European Respiratory Journal, 2017
The cardiovascular risk of concurrently using long-acting β2-agonists (LABAs) and anticholinergics (LAMAs) in COPD is uncertain. We assessed the comparative cardiovascular and cerebrovascular safety of adding a second long-acting bronchodilator in ...
Sophie Dell'Aniello, Samy Suissa, Pierre Ernst   +2 more
core   +2 more sources

The Role of Long-Acting Antimuscarinic Agents in the Treatment of Asthma

Journal of Aerosol Medicine, 2023
The journey of using anticholinergics in the treatment of asthma started with anticholinergic-containing plants such as Datura stramonium and Atropa belladonna, followed by ipratropium bromide and continued with tiotropium, glycopyrronium, and ...
PAÇACI ÇETİN, GÜLDEN, YILMAZ, İNSU, ARSLAN, BAHAR   +2 more
core   +2 more sources

Safety and tolerability of inhalational anticholinergics in COPD

Drug, Healthcare and Patient Safety, 2013
Amir Sharafkhaneh,1,2 Hashir Majid,3 Nicholas J Gross4 1Baylor College of Medicine, Department of Medicine, Houston, USA; 2Sleep Disorders Center, Michael E DeBakey VA Medical Center, Houston, USA; 3Aga Khan University, Karachi, Pakistan; 4Stritch School
Sharafkhaneh A, Majid H, Gross NJ
doaj   +1 more source

Beta2-adrenoreceptor agonists and long-term risk of Parkinson's disease [PDF]

Parkinsonism & Related Disorders, 2023
Introduction There is limited information on how the association between Parkinson's disease and the use of beta2-adrenoreceptor (β2AR) agonists varies among groups of short-, long-, and ultra-long-acting β2AR agonists (SABA, LABA and ultraLABA ...
Trond Riise, Romanowska, Julia, Thomas B. Grydeland, Clemens R. Scherzer, Riise, Trond, Jannicke Igland, Cortese, Marianna, Grydeland, Thomas Blix, Scherzer, Clemens R., Magne H. Solheim, Solheim, Magne, Julia Romanowska, Julia A. Tuominen, Marianna Cortese, Tuominen, Julia Axiina, Bjørnevik, Kjetil Lauvland, Kjetil Bjørnevik, Igland, Jannicke   +17 more
core   +2 more sources

Compare the efficacy and safety of long-acting anticholinergic and a combination of inhaled steroids and long-acting beta-2 agonist in moderate chronic obstructive pulmonary disease

Tuberkuloz ve Toraks, 2016
Introduction: The treatment of COPD (Chronic Obstructive Pulmonary Disease) aims to improve the patients's well-being and to reduce mortality, morbidity and the development of exacerbations.
Sarac, Pinar, Sayiner, Abdullah
core   +4 more sources

Impact of Increased Use of Single-Inhaler Triple Therapies on COPD Exacerbation Rates, Mortality, and Total Costs: PROMETHEUS France [PDF]

International Journal of COPD
Gaëtan Deslee,1 Héloïse Russo,2 Caroline Fabry-Vendrand,2 David Koskas,2 Gabriel Thabut,2 John P Bell,3 Melissa Caplen,4 Prachi Devendra Bhatt,4 Jennifer Carioto,4 Bruce Pyenson,4 Pierre-Régis Burgel5 1Service de Pneumologie, INSERM UMRS-1250, Hospital ...
Deslee G, Russo H, Fabry-Vendrand C, Koskas D, Thabut G, Bell JP, Caplen M, Bhatt PD, Carioto J, Pyenson B, Burgel PR   +10 more
doaj   +2 more sources

Potential for long-acting muscarinic antagonists in chronic obstructive pulmonary disease

Expert Opinion on Investigational Drugs, 2010
: Importance of the field. The prevention and relief of symptoms by regular use of bronchodilators is central to the pharmacological management of chronic obstructive pulmonary disease (COPD).
Joos, Guy
core   +2 more sources